Le pazienti oncologiche chiedono più attenzione

Stoccolma, 13 marzo 2009 - Pfizer Inc announced today that the company will present research on its leading anti-tumour agent, sunitinib malate (SUTENT®), at the 2009 European Association of Urology Congress (EAU) in Stockholm, March 18-20. Included in the research are data evaluated by the United Kingdom's National Institute for Health and Clinical Excellence (NICE) during the agency's recent evaluation of Sutent in mRCC which led to its recommendation to approve Sutent for the 1st-line treatment of advanced renal cell carcinoma (RCC). Among Data to be presented about Sutent at the EAU meeting:

· Results of the final survival analysis and updated efficacy and safety results from a Phase 3 trial evaluating sunitinib versus interferon-alfa as 1st-line treatment for advanced RCC. Professor C Szczylik, Poland.

· An analysis of outcomes for RCC patients with or without prior nephrectomy receiving sunitinib in an ongoing, international, open-label expanded-access trial. Professor C Szczylik, Poland.

· Safety and efficacy analysis for patients with advanced RCC and brain metastases receiving sunitinib in an ongoing, international, open-label expanded-access trial. Dr Bracarda, Italy.

Pfizer will also host a satellite symposium at the meeting, entitled "Improving Outcomes with Targeted Agents for Advanced Renal Cell Carcinoma," on March 19. During the symposium, researchers from across the EU will highlight the urologist's important role in ensuring patients with advanced RCC derive maximum benefit from targeted therapies such as sunitinib, and will discuss optimizing treatment outcomes in the 'real world' setting.

Around 63,000 people are diagnosed with kidney cancer in Europe each year, and half of those will die from the disease annually. Patients with advanced RCC have 5-year survival rates  as low as five to 10 percent. Although improvements in imaging techniques have led to an increase in early diagnoses during routine tests, up to 30 percent of patients will have advanced disease at diagnosis.

Sunitinib malate, an oral therapy, was approved in Europe as a 1st-line treatment for advanced RCC in January 2007. The U.K.'s NICE recommends the 1st-line use of sunitinib in advanced RCC, reversing a previous decision and making sunitinib the only one of four currently available targeted therapies recommended to date. Sunitinib is a novel addition to a new class of "multi-targeted" anti-cancer drugs. It targets the tumour with a dual action strategy, by stopping the cancer cells from multiplying and cutting off the tumour's blood supply. Sunitinib, which is also indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate, is being investigated for a number of other tumour types including advanced breast cancer, advanced hepatocellular carcinoma, advanced non-small cell lung cancer, advanced colorectal cancer and advanced hormone-refractory prostate cancer, in Phase 3 trials.